OVID
Ovid Therapeutics Inc.
Next earnings Aug 11, 2026 · consensus $-0.12 EPS
Last earnings +14.4% on 2026-03-18
$2.55
▲ +5.37%$2.55▲ +779.31%
over 1Y
L $0.29EODHDH $2.96
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.4%
1W+13.3%
1M+0.4%
3M+10.9%
YTD+44.9%
1Y+779.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Revenue grew 1181.3% YoY; but unprofitable (net margin -240.1%).
Revenue (FY2025) $7.25M · FY2025
Ovid Therapeutics Inc. shows $7.25M in FY2025 revenue (+1181.3% YoY), a -240.1% net margin, and -13.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $208M | $1.50M | $392K | $566K | $7.25M |
| Gross profit | — | — | — | — | — |
| Operating income | $124M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| Net income | $123M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Diluted EPS | $1.76 | -$0.77 | -$0.74 | — | — |
| Net margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$323M
EV / EBITDA—
EV / Sales44.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-5.2%
FCF yield-11.4%
Quality & risk
ROIC (est.)-25.7%
Free cash flow-$38.3M
Total debt—
Net cash$13.2M
Altman Z-Score6.61 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+85.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗3Period ending 2026-06-152026-06-17open ↗8-KPeriod ending 2026-06-112026-06-11open ↗8-KPeriod ending 2026-05-292026-06-03open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗SCHEDULE 13G/AFiling2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗
Frequently asked
- Is Ovid Therapeutics Inc. (OVID) a buy?
- OVID currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 1181.3% YoY; but unprofitable (net margin -240.1%).
- What is Ovid Therapeutics Inc.'s quality score?
- OVID scores 49.11764705882352/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001636651, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 6:03:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.